OTCMKTS:CXRXF - Advanz Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $13.17 0.00 (0.00 %) (As of 05/19/2019 04:00 PM ET)Previous Close$13.17Today's Range$13.17 - $13.1752-Week Range$13.14 - $68.40Volume3 shsAverage Volume364 shsMarket Capitalization$644.14 millionP/E Ratio1.12Dividend YieldN/ABeta0.39 ProfileAnalyst RatingsChartEarningsHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada. Receive CXRXF News and Ratings via Email Sign-up to receive the latest news and ratings for CXRXF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:CXRXF Previous Symbol CUSIPN/A CIKN/A Webwww.concordiarx.com Phone905-842-5150Debt Debt-to-Equity Ratio4.50 Current Ratio2.10 Quick Ratio1.79Price-To-Earnings Trailing P/E Ratio1.12 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$536.99 million Price / Sales1.20 Cash Flow$1,317.00 per share Price / Cash Flow0.01 Book Value($11,289.17) per share Price / Book0.00Profitability EPS (Most Recent Fiscal Year)$11.78 Net Income$1.47 billion Net Margins291.15% Return on EquityN/A Return on Assets-6.42%Miscellaneous Employees435 Outstanding Shares48,910,000Market Cap$644.14 million Next Earnings Date8/14/2019 (Estimated) OptionableOptionable Advanz Pharma (OTCMKTS:CXRXF) Frequently Asked Questions What is Advanz Pharma's stock symbol? Advanz Pharma trades on the OTCMKTS under the ticker symbol "CXRXF." How were Advanz Pharma's earnings last quarter? Advanz Pharma Corp (OTCMKTS:CXRXF) released its earnings results on Thursday, March, 14th. The company reported ($1.74) earnings per share for the quarter. The business earned $117.57 million during the quarter. View Advanz Pharma's Earnings History. When is Advanz Pharma's next earnings date? Advanz Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, August 14th 2019. View Earnings Estimates for Advanz Pharma. What is the consensus analysts' recommendation for Advanz Pharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanz Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advanz Pharma. Has Advanz Pharma been receiving favorable news coverage? Media headlines about CXRXF stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Advanz Pharma earned a daily sentiment score of 1.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. Who are some of Advanz Pharma's key competitors? Some companies that are related to Advanz Pharma include Intercept Pharmaceuticals (ICPT), Amneal Pharmaceuticals (AMRX), The Medicines (MDCO), Myokardia (MYOK), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), Insmed (INSM), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Portola Pharmaceuticals (PTLA), Endocyte (ECYT), Xencor (XNCR), Akcea Therapeutics (AKCA), AnaptysBio (ANAB) and Allakos (ALLK). What other stocks do shareholders of Advanz Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advanz Pharma investors own include Orchard Therapeutics (ORTX), Pareteum (TEUM), SunPower (SPWR), Kaiser Aluminum (KALU), Illumina (ILMN), L.B. Foster (FSTR), Dollar Tree (DLTR), Dell (DELL), Ascent Capital Group Inc Series A (ASCMA) and Rathbone Brothers (RAT). Who are Advanz Pharma's key executives? Advanz Pharma's management team includes the folowing people: Mr. Graeme Neville Duncan, CEO & Director (Age 45)Mr. Karl Ian Belk, Chief Operations Officer (Age 51)Mr. Adeel Ahmad, Chief Financial Officer (Age 45)Mr. Robert Sully, Gen. Counsel (Age 46)Mr. Paul Burden, Pres of U.K. & Ireland and Corp. Communications (Age 44) How do I buy shares of Advanz Pharma? Shares of CXRXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Advanz Pharma's stock price today? One share of CXRXF stock can currently be purchased for approximately $13.17. How big of a company is Advanz Pharma? Advanz Pharma has a market capitalization of $644.14 million and generates $536.99 million in revenue each year. The company earns $1.47 billion in net income (profit) each year or $11.78 on an earnings per share basis. Advanz Pharma employs 435 workers across the globe. What is Advanz Pharma's official website? The official website for Advanz Pharma is http://www.concordiarx.com. How can I contact Advanz Pharma? Advanz Pharma's mailing address is 277 LAKESHORE RD. E. SUITE 302, OAKVILLE A6, L6J 1H9. The company can be reached via phone at 905-842-5150 or via email at [email protected] MarketBeat Community Rating for Advanz Pharma (OTCMKTS CXRXF)Community Ranking: 2.0 out of 5 ( )Outperform Votes: 11 (Vote Outperform)Underperform Votes: 17 (Vote Underperform)Total Votes: 28MarketBeat's community ratings are surveys of what our community members think about Advanz Pharma and other stocks. Vote "Outperform" if you believe CXRXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CXRXF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Why Net Income is Important to Investors Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.